137 related articles for article (PubMed ID: 10572309)
41. Two domains in alpha interferons influence the efficacy of the antiviral response.
Zwarthoff EC; Gennissen A; Bosveld IJ; Trapman J; van Heuvel M
Biochem Biophys Res Commun; 1987 Aug; 147(1):47-55. PubMed ID: 2820400
[TBL] [Abstract][Full Text] [Related]
42. Greater sensitivity of caprine synovial membrane cells to human interferon-alpha than human or bovine cells.
Yilma T; Breeze RG; Leib SR
Am J Vet Res; 1984 Oct; 45(10):2094-5. PubMed ID: 6093643
[TBL] [Abstract][Full Text] [Related]
43. The biologic activity and molecular characterization of a novel synthetic interferon-alpha species, consensus interferon.
Blatt LM; Davis JM; Klein SB; Taylor MW
J Interferon Cytokine Res; 1996 Jul; 16(7):489-99. PubMed ID: 8836913
[TBL] [Abstract][Full Text] [Related]
44. Activity of human recombinant and lymphoblastoid interferons in human and heterologous cell lines.
Overall JC; Yeh TJ; Kern ER
J Interferon Res; 1984; 4(4):529-33. PubMed ID: 6094683
[TBL] [Abstract][Full Text] [Related]
45. Synergistic anticellular and antiviral activities of human recombinant interferon-gamma and -beta.
Gomi K; Kimura H; Okabe M; Oka T; Morimoto M
J Pharmacobiodyn; 1986 Nov; 9(11):871-8. PubMed ID: 3031263
[TBL] [Abstract][Full Text] [Related]
46. Disparate response of encephalomyocarditis virus and MM virus to interferon in JLS-V9R cells.
Czarniecki CW; Allen PT
Antiviral Res; 1984 Dec; 4(6):351-5. PubMed ID: 6099710
[TBL] [Abstract][Full Text] [Related]
47. [Comparison of antiviral activity between FeIFN-omega and FeIFN-alpha].
Wang H; Jia X; Yang L; Sun L; Wang H; Liu W
Sheng Wu Gong Cheng Xue Bao; 2008 Sep; 24(9):1556-60. PubMed ID: 19160837
[TBL] [Abstract][Full Text] [Related]
48. Cross-species antiviral and antiproliferative activity of human interferon-omega.
Kubes M; Fuchsberger N; Kontsek P
J Interferon Res; 1994 Apr; 14(2):57-9. PubMed ID: 8077766
[TBL] [Abstract][Full Text] [Related]
49. WISH cell line: from the antiviral system to a novel reporter gene assay to test the potency of human IFN-α and IFN-β.
Bürgi Mde L; Prieto C; Etcheverrigaray M; Kratje R; Oggero M; Bollati-Fogolín M
J Immunol Methods; 2012 Jul; 381(1-2):70-4. PubMed ID: 22549076
[TBL] [Abstract][Full Text] [Related]
50. Pegylated protein encapsulated multivesicular liposomes: a novel approach for sustained release of interferon alpha.
Vyas SP; Rawat M; Rawat A; Mahor S; Gupta PN
Drug Dev Ind Pharm; 2006 Jul; 32(6):699-707. PubMed ID: 16885125
[TBL] [Abstract][Full Text] [Related]
51. Protein kinase C and the antiviral effect of human interferon.
Cernescu C; Constantinescu SN; Baltă F; Popescu LM; Cajal N
Virologie; 1989; 40(3):163-70. PubMed ID: 2480687
[TBL] [Abstract][Full Text] [Related]
52. Mouse adenovirus type 1 replication in vitro is resistant to interferon.
Kajon AE; Spindler KR
Virology; 2000 Aug; 274(1):213-9. PubMed ID: 10936102
[TBL] [Abstract][Full Text] [Related]
53. Rational design of a potent, long-lasting form of interferon: a 40 kDa branched polyethylene glycol-conjugated interferon alpha-2a for the treatment of hepatitis C.
Bailon P; Palleroni A; Schaffer CA; Spence CL; Fung WJ; Porter JE; Ehrlich GK; Pan W; Xu ZX; Modi MW; Farid A; Berthold W; Graves M
Bioconjug Chem; 2001; 12(2):195-202. PubMed ID: 11312680
[TBL] [Abstract][Full Text] [Related]
54. [Antiviral properties of recombinant human lymphotoxin].
Denisov AA; Nikolaeva OG
Vopr Virusol; 1995; 40(6):277-9. PubMed ID: 8686267
[TBL] [Abstract][Full Text] [Related]
55. Antiviral activity of tumour necrosis factor. Synergism with interferons and induction of oligo-2',5'-adenylate synthetase.
Mestan J; Brockhaus M; Kirchner H; Jacobsen H
J Gen Virol; 1988 Dec; 69 ( Pt 12)():3113-20. PubMed ID: 2462015
[TBL] [Abstract][Full Text] [Related]
56. Biologic response (antiviral) to recombinant human interferon alpha 2a as a function of dose and route of administration in healthy volunteers.
Witter F; Barouki F; Griffin D; Nadler P; Woods A; Wood D; Lietman P
Clin Pharmacol Ther; 1987 Nov; 42(5):567-75. PubMed ID: 2445516
[TBL] [Abstract][Full Text] [Related]
57. Evaluation of cytotoxicity and antiviral activity of recombinant human interferon alfa-2a and recombinant human interferon alfa-B/D hybrid against bovine viral diarrhea virus, infectious bovine rhinotracheitis virus, and vesicular stomatitis virus in vitro.
Peek SF; Bonds MD; Gangemi DG; Thomas CB; Schultz RD
Am J Vet Res; 2004 Jun; 65(6):871-4. PubMed ID: 15198231
[TBL] [Abstract][Full Text] [Related]
58. [Leukocyte migration inhibiting factor in preparations of alpha and gamma interferons].
Vakhromeeva NS; Bagaeva LV; Kuznetsov VP; Medunitsyn NV; Bobkova EV
Vopr Virusol; 1986; 31(5):617-9. PubMed ID: 3026096
[TBL] [Abstract][Full Text] [Related]
59. Comparative susceptibility of respiratory viruses to recombinant interferons-alpha 2b and -beta.
Sperber SJ; Hayden FG
J Interferon Res; 1989 Jun; 9(3):285-93. PubMed ID: 2545792
[TBL] [Abstract][Full Text] [Related]
60. [Antiviral activity of preparations of RNA isolated from cells treated with interferon (messenger RNA for an antiviral protein?)].
Orlova TG; Mamontova TV; Zhdanova LV; Solov'ev VD
Biull Eksp Biol Med; 1977 Apr; 83(4):436-7. PubMed ID: 192394
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
